GREAT-2: A phase 2 trial of Gremubamab compared to placebo in participants with bronchiectasis and chronic Pseudomonas aeruginosa infection

Project Details

StatusActive
Effective start/end date1/11/2231/10/25

Funding

  • European Respiratory Society (ERS EMBARC3): £2,437,333.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.